Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
We identified the difference of immune cells effecting on HIV clinical outcomes between South African and Thai HIV patients. (1)Among South African population, patients with HLA-C*16:01+KIR2DL3+ had worse clinical outcome, and (2)among Thai population, patients with HLA-B*46:01+KIR2DL2+ had worse clinical outcome, and ones with HLA-C*12:03+KIR2DL2+ had better outcome. These suggested the possibility of regional difference in efficacy of newly-developed medicine effecting through HLA-KIR pathways. These information would support the discovery and development of novel HIV medicines and treatment.
|